

Xiao-Mao Guo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6559206/publications.pdf>

Version: 2024-02-01

64
papers

1,112
citations

394421

19
h-index

454955

30
g-index

64
all docs

64
docs citations

64
times ranked

1947
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment. <i>Breast Cancer Research</i> , 2022, 24, 20.	5.0	34
2	Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. <i>Molecular Cancer</i> , 2022, 21, 84.	19.2	34
3	Clinicopathological Characteristics of Breast Ductal Carcinoma In Situ: An Analysis of Chinese Population of 617 Patients. <i>Journal of Oncology</i> , 2021, 2021, 1-6.	1.3	2
4	Outcomes in Patients with pT3N0M0 Breast Cancer with and without Postmastectomy Radiotherapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 3889-3899.	1.9	2
5	Symptoms Related to Brachial Plexus Neuropathy After Supraclavicular Irradiation and Boost in Breast Cancer. <i>Practical Radiation Oncology</i> , 2021, , .	2.1	3
6	Does the protocol-required uniform margin around the CTV adequately account for setup inaccuracies in whole breast irradiation?. <i>Radiation Oncology</i> , 2021, 16, 143.	2.7	5
7	Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 277-286.	2.5	6
8	Characteristics, prognosis, risk factors, and management of recently diagnosed ductal carcinoma in situ with microinvasion. <i>Cancer Medicine</i> , 2021, 10, 7203-7212.	2.8	9
9	Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. <i>Molecular Cancer</i> , 2021, 20, 5.	19.2	12
10	Prognostic value of metabolic signature on 18F-FDG uptake in breast cancer patients after radiotherapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 412-419.	4.4	2
11	Carbon Ion Radiotherapy Evokes a Metabolic Reprogramming and Individualized Response in Prostate Cancer. <i>Frontiers in Public Health</i> , 2021, 9, 777160.	2.7	4
12	Internal mammary node irradiation improves 8-year survival in breast cancer patients: results from a retrospective cohort study in real-world setting. <i>Breast Cancer</i> , 2020, 27, 252-260.	2.9	6
13	Postoperative radiotherapy improves overall survival in patients with primary squamous cell carcinoma of the breast. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 17, 454-461.	1.1	6
14	The Expressions and Mechanisms of Sarcomeric Proteins in Cancers. <i>Disease Markers</i> , 2020, 2020, 1-16.	1.3	4
15	CDK4/6 inhibitors: a novel strategy for tumor radiosensitization. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 188.	8.6	35
16	Building radiation-resistant model in triple-negative breast cancer to screen radioresistance-related molecular markers. <i>Annals of Translational Medicine</i> , 2020, 8, 108-108.	1.7	12
17	Adjuvant breast inversely planned intensity-modulated radiotherapy with simultaneous integrated boost for early stage breast cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 764-770.	2.0	9
18	The survival benefit of radiotherapy in localized primary adult rhabdomyosarcoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 266-272.	1.1	7

#	ARTICLE	IF	CITATIONS
19	Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients. <i>Cancer Medicine</i> , 2020, 9, 2427-2434.	2.8	7
20	Radiation-induced skin injury: pathogenesis, treatment, and management. <i>Aging</i> , 2020, 12, 23379-23393.	3.1	2
21	Single institution experience of split course radiotherapy in patients with desmoid tumors. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1741-1748.	2.0	4
22	Elevated Risk of Radiation Therapy-Associated Second Malignant Neoplasms in Young African-American Women Survivors of Stage I-III Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 275-284.	0.8	2
23	The Impact of Radiotherapy on Reoperation Rates in Patients Undergoing Mastectomy and Breast Reconstruction. <i>Annals of Surgical Oncology</i> , 2019, 26, 961-968.	1.5	10
24	Internal Mammary Node Irradiation (IMNI) Improves Survival Outcome for Patients With Clinical Stage II-III Breast Cancer After Preoperative Systemic Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 895-904.	0.8	17
25	Association between breast cancer cell migration and radiosensitivity <i>in vitro</i> . <i>Oncology Letters</i> , 2019, 18, 6877-6884.	1.8	4
26	Prognostic factors in breast phyllodes tumors: a nomogram based on a retrospective cohort study of 404 patients. <i>Cancer Medicine</i> , 2018, 7, 1030-1042.	2.8	27
27	Targeting deubiquitinase USP28 for cancer therapy. <i>Cell Death and Disease</i> , 2018, 9, 186.	6.3	81
28	Local recurrence is correlated with decreased overall survival in patients with intermediate high-grade localized primary soft tissue sarcoma of extremity and abdominothoracic wall. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e109-e115.	1.1	10
29	Association between breast cancer and thyroid cancer: A study based on 13,978 patients with breast cancer. <i>Cancer Medicine</i> , 2018, 7, 6393-6400.	2.8	21
30	Outcomes Following Salvage Radiation and Systemic Therapy for Isolated Locoregional Recurrence of Breast Cancer after Mastectomy: Impact of Constructed Biologic Subtype. <i>Journal of Oncology</i> , 2018, 2018, 1-10.	1.3	4
31	Highlights on molecular targets for radiosensitization of breast cancer cells: Current research status and prospects. <i>Cancer Medicine</i> , 2018, 7, 3110-3117.	2.8	5
32	The influence of anatomic location on outcomes in patients with localized primary soft tissue sarcoma. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 799-805.	1.3	3
33	Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II–III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1973-1980.	2.0	10
34	The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 513-523.	6.1	63
35	Is it possible for knowledge-based planning to improve intensity modulated radiation therapy plan quality for planners with different planning experiences in left-sided breast cancer patients?. <i>Radiation Oncology</i> , 2017, 12, 85.	2.7	49
36	Intensity modulated radiotherapy with fixed collimator jaws for locoregional left-sided breast cancer irradiation. <i>Oncotarget</i> , 2017, 8, 33276-33284.	1.8	8

#	ARTICLE	IF	CITATIONS
37	Estrogen Receptor Mediates the Radiosensitivity of Triple-Negative Breast Cancer Cells. <i>Medical Science Monitor</i> , 2017, 23, 2674-2683.	1.1	22
38	Intraoperative radiotherapy for the treatment of thyroid cancer: a pilot study. <i>Oncotarget</i> , 2017, 8, 29355-29360.	1.8	2
39	Prospective evaluation of skin toxicities in patients receiving post-mastectomy irradiation of chest wall, supra/infraclavicular and internal mammary nodes delivered by conventional versus intensity-modulated radiotherapy technique. <i>Oncotarget</i> , 2017, 8, 80012-80019.	1.8	2
40	Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 540.	3.3	14
41	Diagnostic performance of core needle biopsy in identifying breast phyllodes tumors. <i>Journal of Thoracic Disease</i> , 2016, 8, 3139-3151.	1.4	18
42	Phyllodes tumors of the breast: diagnosis, treatment and prognostic factors related to recurrence. <i>Journal of Thoracic Disease</i> , 2016, 8, 3361-3368.	1.4	39
43	Is internal mammary nodes irradiation as a part of breast cancer postoperative radiotherapy necessary?. <i>Journal of Thoracic Disease</i> , 2016, 8, 3427-3430.	1.4	5
44	HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 45186-45198.	1.8	58
45	Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. <i>World Journal of Surgical Oncology</i> , 2016, 14, 209.	1.9	31
46	The efficacy of postoperative radiotherapy in localized primary soft tissue sarcoma treated with conservative surgery. <i>Radiation Oncology</i> , 2016, 11, 25.	2.7	15
47	Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis. <i>Breast Cancer</i> , 2016, 23, 732-739.	2.9	22
48	Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab. <i>Oncotarget</i> , 2016, 7, 1042-1054.	1.8	23
49	Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 38380-38391.	1.8	25
50	Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis. <i>Journal of Cancer Research and Therapeutics</i> , 2016, 12, 775.	0.9	10
51	Management experiences of primary angiosarcoma of breast: a retrospective study from single institute in the People's Republic of China. <i>OncoTargets and Therapy</i> , 2015, 8, 3237.	2.0	2
52	Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 323-336.	4.4	24
53	Systematic review and meta-analysis comparing hypofractionated with conventional fraction radiotherapy in treatment of early breast cancer. <i>Surgical Oncology</i> , 2015, 24, 200-211.	1.6	27
54	Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2015, 114, 289-295.	0.6	109

#	ARTICLE	IF	CITATIONS
55	Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab. <i>Oncologist</i> , 2015, 20, 605-614.	3.7	33
56	In Regard to Brown et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 722-723.	0.8	1
57	Stanniocalcin 2 Suppresses Breast Cancer Cell Migration and Invasion via the PKC/Claudin-1-Mediated Signaling. <i>PLoS ONE</i> , 2015, 10, e0122179.	2.5	42
58	Dose coverage of axillary level I-III areas during whole breast irradiation with simplified intensity modulated radiation therapy in early stage breast cancer patients. <i>Oncotarget</i> , 2015, 6, 18183-18191.	1.8	15
59	Multibeam inverse intensity-modulated radiotherapy (IMRT) for whole breast irradiation: a single center experience in China. <i>Oncotarget</i> , 2015, 6, 35063-35072.	1.8	6
60	Isolated locoregional recurrence patterns of breast cancer after mastectomy and adjuvant systemic therapies in the contemporary era. <i>Oncotarget</i> , 2015, 6, 36860-36869.	1.8	6
61	Complete response after chemotherapy and radiotherapy of a tonsillar histiocytic sarcoma with regional lymph node involvement: a case report and review of the literature. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 16808-12.	1.3	5
62	Targeting the Neddylaton Pathway to Suppress the Growth of Prostate Cancer Cells: Therapeutic Implication for the Men's Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	20
63	Treatment outcome of patients with stages I-II nasopharyngeal carcinoma after late course accelerated hyperfractionation radiotherapy alone. <i>Oral Oncology</i> , 2012, 48, 1058-1063.	1.5	15
64	Molecular subtypes predict second breast events of ductal carcinoma in situ after breast-conserving surgery. <i>Cancer Medicine</i> , 0, , .	2.8	2